GOSS vs. ETNB, DNLI, SRPT, OCUL, DYN, VERA, ANIP, TLRY, COGT, and TWST
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include 89BIO (ETNB), Denali Therapeutics (DNLI), Sarepta Therapeutics (SRPT), Ocular Therapeutix (OCUL), Dyne Therapeutics (DYN), Vera Therapeutics (VERA), ANI Pharmaceuticals (ANIP), Tilray Brands (TLRY), Cogent Biosciences (COGT), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.
Gossamer Bio vs. Its Competitors
Gossamer Bio (NASDAQ:GOSS) and 89BIO (NASDAQ:ETNB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.
Gossamer Bio currently has a consensus target price of $8.50, indicating a potential upside of 267.17%. 89BIO has a consensus target price of $25.81, indicating a potential upside of 74.11%. Given Gossamer Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Gossamer Bio is more favorable than 89BIO.
81.2% of Gossamer Bio shares are owned by institutional investors. 6.7% of Gossamer Bio shares are owned by company insiders. Comparatively, 2.6% of 89BIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
89BIO has a net margin of 0.00% compared to Gossamer Bio's net margin of -344.81%. 89BIO's return on equity of -94.48% beat Gossamer Bio's return on equity.
In the previous week, 89BIO had 3 more articles in the media than Gossamer Bio. MarketBeat recorded 3 mentions for 89BIO and 0 mentions for Gossamer Bio. 89BIO's average media sentiment score of 0.49 beat Gossamer Bio's score of 0.00 indicating that 89BIO is being referred to more favorably in the news media.
Gossamer Bio has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500. Comparatively, 89BIO has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.
Gossamer Bio has higher revenue and earnings than 89BIO. 89BIO is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Gossamer Bio beats 89BIO on 11 of the 16 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GOSS) was last updated on 10/24/2025 by MarketBeat.com Staff
Free GOSS Stock Alerts